c-erbB-2、p53、p21基因在乳腺癌、胃癌和大肠癌中过度表达的临床意义

对９０例乳腺癌、胃癌和大肠癌同时检测癌肿内及转移淋巴结的ｃ－ｅｒｂＢ－２、ｐ５３、ｐ２１的过度表达。结果显示乳腺癌、胃癌和大肠癌转移淋巴中ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１的阳性率分别与原发癌肿内的阳性率之间无显著性差异（Ｐ＞０．０５）。转移淋巴结与原发癌肿之间ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１过度表达与否的平均符合率分别为７３．１％、６５．４％、７３．１％。显示转移淋巴结中基因过度表达与否同原发癌肿基本一致。在原发癌肿内ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１基因的过度表达（除乳腺癌中的ｐ２１表达）分别与癌肿的预后有一定关系，但在不同癌肿中所表示的预后指标有较大差异。９０例中多种基因蛋白过度表达占５２．２％，且提示上述癌肿预后较差。同时检测ｃ－ｅｒｂＢ－２、ｐ５３和ｐ２１过度表达对癌肿的预后判断明显优于单个基因蛋白的检测。     

C-erbB-2、p53和PCNA对乳腺浸润性癌预后价值的Cox回归分析

目的 探讨癌基因ｃ－ｅｒｂＢ－２产物、抑癌基因ｐ５３突变型蛋白的过度以及增殖细胞核抗原标记指数（ＰＣＮＡ－ＬＩ）与乳腺浸润性癌临床病理指标的联系及其预后价值。方法 随机收集７９例临床随访资料齐备的病人,用免疫组化ＡＢＣ法检测其ｃ－ｅｒｂＢ－２、ｐ５３和ＰＣＮＡ的表达情况,用Ｃｏｘ回归分析其预后意义。结果 ｃ－ｅｒｂＢ－２和ｐ５３过度表达的阳性率分别为３１．７％和４８．１％。ＰＣＡＮ－ＬＩ中位数为１７．６％。ｃ－ｅｒｂＢ－２与ｐ５３过度表达之间以及其与ＰＣＮＡ－ＬＩ、肿瘤大小、组织学分级、腋淋巴结状态等指标间均无明确的相互关联。ＰＣＮＡ－ＬＩ与这分级呈正相关,但高ＰＣＮＡ－ＬＩ与不良预后无显关联。Ｃｏｘ回归分析显示,腋淋巴结、ｃ－ｅｒｂＢｔ ｐ５３过度表达等３项指标反映不良预后,危险度分别是３．３０６、１．４１９     

乳腺癌p53、c—erbB—2的表达及其与组织学分级的关系

目的：探讨癌基因蛋白ｐ５３、ｃ－ｅｒｂＢ－２与乳腺癌组织学分级的关系。方法：用免疫组织化学法（ＬＳＡＢ）检测ｐ５３、ｃ－ｅｒｂＢ－２癌基因蛋白在４０例乳腺癌的表达,并分析其与乳腺癌组织学分析的关系。采用ｘ＾２检验进行统计学处理。结果：ｐ５３、ｃ－ｅｒｂＢ－２过度表达在乳腺癌Ⅱ级、Ⅲ级明显高于Ⅰ级,各级间差异有显著性（Ｐ〈０．０１）;４０例乳腺癌两种癌基因蛋白共同表达者２１例,占５２．５％,均为Ⅱ级和Ⅲ级。结论：ｐ５３、ｃ－ｅｒｂＢ－２与乳腺癌组织学分级有密切关系,是判断乳腺癌预后的重要指标;多个癌基因蛋白的表达异常及协同作用与乳腺癌生物学行为有一定的相关性。     

c—erbB—2,p53,p21基因在乳腺癌,胃癌和大肠癌中过度表达的临床 …

对９０例乳腺癌、胃癌和大肠癌同时检测癌肿同及转移淋巴结的ｃ－ｅｒｂＢ－２、ｐ５３、ｐ２１的过度表达。结果显示乳腺癌、胃癌和大肠癌转移淋巴中ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１的阳性率分别与原发癌肿内的阳性率之间无显著性差异（Ｐ〉０．０５）。转移淋巴结与原发癌肿之间ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１过度表达与否的平均符合率分别为７３．１％、６５．４％、７３．１％。显示转移淋巴结中基因过度表达与否同原发癌肿     

胃癌p53和c—erbB—2基因产物的表达及其与病理临床的相关性研究

用免疫组化ＡＢＣ法对９２例胃癌的石蜡包埋标本进行了ｐ５３和ｃ－ｅｒｂＢ－２基因蛋白表达的研究。结果显示：９２例胃癌ｐ５３、ｃ－ｅｒｂＢ－２蛋白表达的阳性率分别为３８．０％和１４．１％；ｐ５３表达主要位于细胞核内，而ｃ－ｅｒｂＢ－２表达主要位于细胞膜，ｐ５３及ｃ－ｅｒｂＢ－２表达与胃癌患者的性别、年龄、原发灶部位、淋巴结及远处转移、肿瘤分期以及病理类型、分级均无明显关系。ｐ５３阳性表达的胃癌患者生存期明显低于ｐ５３阴性者，而ｃ－ｅｒｂＢ－２表达与胃癌患者的生存期无关；ｐ５３与ｃ－ｅｒｂＢ－２二者阳性表达之间亦无关。５例ｐ５３及ｃ－ｅｒｂＢ－２表达的阳性者预后极差，提示，癌基因的异常表达对预后的估计具有辅助意义。     

c-erbB-2、p53和Bcl-2蛋白表达在乳腺癌中的意义及其相关性的探讨

目的　探讨乳腺癌中ｃｅｒｂ Ｂ２、ｐ５３ 和Ｂｃｌ２ 蛋白表达与临床病理参数、预后和增殖细胞核抗原（ＰＣＮＡ） 、雌激素受体（ＥＲ）、孕激素受体（ＰＲ）的关系。　方法　应用亲和素生物素复合物（ＡＢＣ） 法免疫组织化学技术对８７例福尔马林固定石蜡包埋的乳腺癌组织进行回顾性研究。　结果　（１）ｃｅｒｂ Ｂ２ 和ｐ５３ 这两种蛋白的超表达与淋巴结转移、病理分级、核分裂、生存期短、ＰＣＮＡ强阳性表达、ＥＲ、ＰＲ阴性表达等不良因素呈正相关趋势（ Ｐ＞ ０－０５） 。（２）Ｂｃｌ２ 的阳性表达与瘤细胞的分化、淋巴结无转移、生存期长,ＥＲ、ＰＲ 的阳性表达等良好因素相关联,而且Ｂｃｌ２的阳性表达常会“减弱”或“抵抗”原癌基因的不良因素。　结论　多种癌基因（ 包括ｃｅｒｂ Ｂ２、ｐ５３ 和Ｂｃｌ２） 参与了乳腺癌的发生和发展     

c-erbB-2、H-ras p21、p53及PCNA在原发性肝癌中的表达

应用免疫组化ＬＳＡＢ法，对５０例原发性肝癌、癌周肝组织及１０例正常肝组织中ｃ－ｅｒｂＢ－２、Ｈ－ｒａｓｐ２１和ｐ５３癌基因蛋白及ＰＣＮＡ表达进行比较研究。结果表明，ｃ－ｅｒｂＢ－２、Ｈ－ｒａｓｐ２１、ｐ５３及ＰＣＮＡ阳性表达率，在癌组织中分别为７０．０％、６８．０％、４６．０％及８２．０％；在癌周肝组织中分别为２２．０％、６４．０％、４．０％及５２．０％；正常肝组织中（除Ｈ－ｒａｓｐ２１外）未见表达，且癌组织与非癌组织（Ｈ－ｒａｓｐ２１除外）及正常肝组织之间有显著差异（Ｐ＜０．０５）。ｃ－ｅｒｂＢ－２和ｐ５３蛋白的表达与原发性肝癌的组织学分级有密切关系（Ｐ＜０．０５），且二者的表达有高度的相关性（Ｐ＜０．００５），在癌、癌周肝组织中，２种以上癌基因蛋白同时表达总率分别为１４４．０％、１２．０％，癌基因蛋白与ＰＣＮＡ同时表达总率分别为１５０．０％、８４．０％。提示肝癌的发生是由多种癌基因独立并协同作用伴有细胞异常增殖的恶性转化过程。     

大肠息肉与大肠癌p53及c—erbB—2蛋白表达

应用免疫组织化学ＳＰ法对１６例良性大肠息肉，９６例大肠癌组织中抑癌基因ｐ５３蛋白及原癌基因ｃｅｒｂＢ２蛋白表达进行研究。结果表明，幼年性息肉，增生性息肉均无ｐ５３蛋白表达，而ｃｅｒｂＢ２蛋白可以有一定程度的表达。ｐ５３、ｃｅｒｂＢ２在腺瘤中的表达阳性率分别为２０．０％（２／１０）及３０．０％（３／１０），其中ｐ５３阳性细胞呈散在或灶性分布，但阳性细胞数不超过５％。ｐ５３及ｃｅｒｂＢ２在腺癌中的表达阳性率分别为４３．８％（４２／９６）及５０．６％（４０／７９），其中同时表达两种蛋白者占２９．１％，且ｐ５３蛋白表达与肿瘤进展有关，ｐ５３阳性者多为Ｂ期或Ｃ、Ｄ期癌，更易于发生淋巴结转移。     

大肠癌p185^erbB2,p21^ras,p53的表达及其临床病理意义

目的：研究大肠癌中ｐ１８５＾ｅｒｂＢ２、ｐ２１＾ｒａｓ、ｐ５３的表达及其临床病理意义。方法采用Ｓ－Ｐ法检测８０例大肠癌组织中ｐ１８５＾ｅｒｂＢ２、ｐ２１＾ｒａｓ、ｐ５３的表达。结果大肠癌原发病灶中ｐ１８５＾ｅｒｂＢ２、ｐ２１＾ｒａｓ、ｐ５３的阳性表达率分别为５８．８％、７１．３％及５３．８％。癌组织同时有２种以上蛋白表达者占６３．７％（５１／８０）,有３种蛋白同时表达者占３０％（２４／８０）。ｐ１     

bcl—2,53,cathepsin D,PSA表达与乳腺癌预后的关系

目的：探讨ｂｃｌ－２、ｐ５３、Ｃａｔｈｅｐｓｉｎ Ｄ（ＣＤ）和有列朱特异笥抗原（ＰＳＡ）表达与乳腺癌预后的关系。方法：应用免疫组化ＬＳＡＢ方法检测６４例乳腺癌及３０例乳腺良性为的表达。分析ｂｃｌ－２、ｐ５３、ＣＤ和ＰＳ七乳腺癌组织学分级、腋地转移、复发和承后的关系。结果：ｂｃｌ－２、ｐ５３表达之间有显著性差异（Ｐ〈０．０５）,呈负相关;ｂｃｌ－２与ＣＤ和ＰＳＡ之间表达之间均无关（Ｐ〉０．０５）,ｂ     

淋巴结阴性乳腺癌p21waf1、c-erbB-2和p53蛋白表达及其临床意义

目的：探讨腋淋巴结阴性乳腺癌组织中p21^waf1、c-erbB-2和p53基因蛋白表达及其与临床病理参数和预后的关系。方法：应用免疫组化LSAB方法检测121例腋淋巴结阴性乳腺部石蜡切片中p21^waf1、c-erbB-2和p53蛋白的表达情况;同时应用Kaplan-Meier法及多变量Cox比例风险模型,分析3种蛋白表达与预后的关系。结果：（1）p21^waf1蛋白表达率为48．8％,与病理组织学分级、ER状态有关;p53蛋白表达率为36．4％,c-erbB－2蛋白表达率为26．4％,与组织学分级有关;（2）p21^waf1阳性表达与p53表达呈负相关（P＜0．01）;Cox阳性组患者无瘤生存率高于阴性组（P＜0．05）;c-erbB－2阳性组患者无瘤生存率明显低于阴性组（P＜0．01）;Cox模型分析显示仅有c-erbB－2表达对预后有显著影响。结论：乳腺癌组织p21^waf1、c-erbB-2表达与病理组织学分级有相关性;p^21waf1表达依赖于p53途径刺激;p^21waf1、c-erbB－2表达与腋淋巴结阴性乳腺癌预后有关,且c-erbB-2表达是一个独立的预后指标。     

The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma

AIMS AND BACKGROUND: p53, c-erbB-2 and Ki-67 protein expression and microvessel density (MVD) determined by CD34 antibody were evaluated by immunohistochemistry and their correlation with clinicopathological parameters including estrogen (ER) and progesterone (PR) receptor status and survival were investigated in patients with axillary lymph node-negative infiltrating ductal breast carcinoma. METHODS: The study population consisted of 47 patients with axillary lymph node-negative infiltrating ductal breast carcinoma. RESULTS: p53 and c-erbB-2 expression was detected in 36.2% and 31.9% of patients, respectively. Median Ki-67 expression was 10%. There were no statistically significant differences in the distribution of p53, Ki-67 and c-erbB-2 protein expression in relation to the age of the patients or to the size, histological grade or ER and PR status of the tumors. p53 protein expression correlated positively with c-erbB-2 and Ki-67 protein expression (P < 0.05). The mean MVD was 63.65 +/- 29.1 and it correlated positively with histological grade and Ki-67 expression (P < 0.05). Survival analysis revealed that age, tumor size, p53 and c-erbB-2 expression and PR status had no significant prognostic impact, whereas histological grade, proliferative activity and angiogenic activity were significant prognostic factors. Although ER-positive patients had a statistically significant overall survival advantage, the difference in disease-free survival was not significant. CONCLUSION: In axillary lymph node-negative breast carcinoma the histological grade and the proliferative and angiogenic activity of the tumor could be useful prognostic indicators.     

The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients

BACKGROUND: The variability of prognosis within a pathological stage of gastric cancer (GC) at presentation, underscores the need for specific biological markers to identify subgroups of patients with aggressive course for intensive treatment. To our knowledge, this is the first study from an Arab population reporting on the relationship of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 expression, and clinicopathological features and their prognostic significance. METHODS: Formalin-fixed paraffin-embedded tumors were studied by immunohistochemistry, using monoclonal antibodies to p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67. The results were correlated with clinicopathological features and survival. RESULTS: M:F = 80:41; median age = 60 years; stage III and IV = 71%; and median follow-up = 34.4 months. Positive expression rates of p53, p27 kip1, p21 waf1, Ki67, and HER-2/neu were 54%, 40%, 8.3%, 70%, and 12% respectively. p53 expression correlated with age <60 years (P = 0.03), tumor size >5 cm (P = 0.01), p27 kip1 and Ki67 expression (P = 0.0001), and HER-2/neu (P = 0.04). p21 waf1 correlated inversely with T-stage (P = 0.008) and Her-2/neu expression correlated with histological grade (P = 0.04) and T-stage (P = 0.008). Univariate analysis showed that p53 overexpression (P = 0.01), fungating and infiltrative macroscopic appearance (P = 0.02), size >5 cm (P = 0.0001), lymph node metastasis (P = 0.0001), p T3 and T4 disease (P = 0.01), and overall stage III and IV (P = 0.0001) disease were adverse prognostic factors. Patients with tumor profiles p53 (-)/p27 (+) had better survival than those with p53 (+)/p27 kip1 (-)(P = 0.02). On multivariate analysis by Cox regression model, the expression of p53 (P = 0.03) and lymph node involvement (P = 0.01) were significant adverse prognostic factors for overall survival. CONCLUSIONS: The expression of p53 in Arab patients with GC correlates with aggressive tumor characteristics and is an independent prognostic factor. The combined analysis of p53 and p27 kip1 is of added prognostic value.     

原发性输尿管癌p53、c-erbB-2和nm23表达与临床病理特征的关系

目的　研究输尿管癌 p5 3、c- erb B- 2、nm2 3基因的不同表达与其临床病理因素的关系。方法　应用免疫组化 S- P法检测 p5 3、c- erb B- 2、nm2 3等基因蛋白在 2 4例原发性输尿管癌中的表达情况 ,并对其结果与临床病理各参数的关系进行分析。结果　正常输尿管上皮三种基因蛋白均呈阴性 ,在输尿管癌中 p5 3、c- erb B- 2、nm2 3的阳性表达率分别为 41.6 % (10 /2 4)、5 4.1% (13/2 4)和 6 6 .7% (16 /2 4)。 p5 3、c- erb B- 2高表达与输尿管癌分化程度低、浸润至浆膜或浆膜外、生存期短等几项临床病理特征相关。nm2 3的表达与输尿管癌病理分级、浸润深度、临床预后无密切关联。结论　 p5 3、c- erb B- 2和 nm2 3基因参与了输尿管癌的发生发展过程 ,p5 3、c- erb B- 2蛋白表达可以作为输尿管癌生物学行为和预后判断的参考指标 ,两指标同时检测预示作用更可靠     

胃癌p53,c—erbB—2和nm23癌基因蛋白的免疫组织化学研究

目的利用胃癌生物学恶性信息,探讨术前检测ｐ５３、ｃ－ｅｒｂＢ－２和ｎｍ２３蛋白对胃癌的诊断价值。方法收集胃癌手术标本１４１例,胃镜活检标本９３例,应用免疫组化技术检测ｐ５３、ｃ－ｅｒｂＢ－２和ｎｍ２３蛋白在上述组织中的表达。结果ｐ５３阳性率为４５．８％～５６．３％,ｃ－ｅｒｂＢ－２为１８．３％～３０．２％,ｎｍ２３为７２．９％～８１．３％,在非胃癌组织中无表达;ｃ－ｅｒｂＢ－２的表达与肿瘤组织的大小、癌细胞的分化程度及Ｌａｕｒéｎ分型有关,且ｃ－ｅｒｂＢ－２表达阳性组５年生存率低于阴性组;ｎｍ２３的表达与肿瘤的生长方式、浸润深度和淋巴结转移有关。三种癌蛋白的阳性率在胃癌的胃镜活检标本和手术标本中无显著差别。结论对胃癌组织进行ｐ５３、ｃ－ｅｒｂＢ－２和ｎｍ２３蛋白的检测,有助于胃癌的诊断、良恶性病变的鉴别诊断、非手术临床分期的判断和评估胃癌患者的预后。     

p53 、bcl-2 和CD44v6 蛋白表达与乳腺癌转移的相关性研究

 目的 探讨乳腺癌及癌旁正常乳腺组织中p53、bcl—2和CD44v6蛋白的表达及意义。方法 采用免疫组化法检测96例乳腺癌及其癌旁正常乳腺组织中p53、bcl—2和CD44v6蛋白的表达，并分析其与淋巴结转移和c-erbB-2表达状态的相关性，从而评价这些指标在预测乳腺癌转移方面的价值。结果 正常乳腺组织中p53蛋白为阴性，在乳腺癌中阳性表达率为65．63％；随着组织学分级的增高，阳性率逐渐增高；淋巴结转移组阳性表达率明显高于无淋巴结转移组，并与c-erbB-2表达状态呈正相关。乳腺癌组织中bcl-2阳性表达率明显低于周围正常乳腺组织，随着组织学分级的增高，阳性率逐渐降低，淋巴结转移组中的表达率明显低于淋巴结非转移组，与c-erbB-2的表达呈负相关。CD44v6在乳腺癌组织中的阳性表达率明显高于正常乳腺组织，随着组织学分期的增加，CD44v6的阳性表达率亦增高，但差异无显著性，淋巴结转移组的阳性率略高于无淋巴结转移组，差异也无显著性，与c-erbB-2表达无相关性。结论 p53和bcl-2蛋白可作为预测乳腺癌转移的指标，CD44v6的阳性表达可能与乳腺癌的发生、进展有一定关系，但尚不能把它作为预测乳腺癌转移的稳定的生物学指标。     

p53、c-erbB-2和PCNA蛋白表达与大肠癌生物学行为的关系

目的　探讨 p5 3、c erbB 2、PCNA蛋白的表达与大肠癌的临床病理意义以及其对大肠癌预后判断的价值。方法　应用免疫组化技术对 5 3例大肠癌进行上述指标的表达及对比研究。结果　大肠癌p5 3、PCNA、c erbB 2阳性表达分别为 5 2 .83%、96 .2 3%、5 4 .72 %。p5 3、PCNA、c erbB 2共同阳性表达率为 37.74 % ,与大肠癌患者年龄、性别、发病部位、纤维的增生程度、淋巴细胞的浸润及组织学类型无关 (P >0 .0 5 ) ,与癌组织的浸润深度、淋巴结转移有关 (P <0 .0 5 )。纤维组织的增生程度与癌组织浸润程度呈负相关 (r1=- 0 .4 2 13,P <0 .0 5 )有参考价值。结论　p5 3、c erbB 2、PCNA的联合检测对判断大肠癌预后有参考价值。     

Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.

p53 tumor-suppressor gene mutation and p53 protein over-expression have been reported with higher frequency in early-onset breast carcinomas (EOBC). Given the role attributed to normal p53 protein in DNA-repair mechanisms, other somatic genomic alterations would be expected to be associated with this abnormality. Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. In a retrospective study of 62 formalin-fixed paraffin-embedded invasive EOBC (diagnosed at 35 years or less), the amplification status of the c-erbB-2 gene detected by fluorescence in situ hybridization (FISH) using a unique sequence probe was compared with p53 protein accumulation measured by immunohistochemistry (IHC) and phenotypic features. p185erbB2-protein expression was also detected by immunohistochemistry, together with estrogen-receptor (ER) and progesterone-receptor (PR) expression. The data for a sub-set of 33 node-negative EOBC cases were compared with 70 node-negative tumors diagnosed in women above 36 years of age. Compared with node-negative BC in older women, node-negative EOBC was significantly more likely to feature high grade, high proliferation rate, negative ER and/or PR and p53 over-expression (p < 0.05). A trend toward a higher incidence of c-erbB-2 amplification in EOBC (21% vs. 9%) reached near-significance (p = 0.07). In EOBC, c-erbB-2 amplification and p53 over-expression were not associated with high tumor grade or high cell-proliferation rate, in contrast to the significant associations of these markers in tumors in older women. Abnormalities in tumor markers, including c-erbB-2 gene amplification and p53-protein over-expression, occur at different rates in women with EOBC as compared with BC developing in older women. This finding may reflect a different pathogenesis for EOBC, and warrants further investigation.     

Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer.

p21waf1 is a downstream effector of p53, and mediates growth arrest by inhibiting the action of G1 cyclin-dependent kinases. Cyclin D1 is a cell-cycle regulator essential for G1 phases progression and a candidate proto-oncogene implicated in the pathogenesis of several human tumor types. Cyclin D1 overexpression and the absence of retinoblastoma (Rb) protein have been frequently seen in various types of cancer, including lung cancer. The aim of this study was to clarify the relationship between the expressions of p21waf1, cyclin D1, and Rb protein, and to investigate the correlation between these protein expressions and the clinical features of the patients, and their prognoses. We immunohistochemically examined 92 samples of resected non-small cell lung cancer for p21waf1, cyclin D1, and Rb expression. Of the 92 specimens examined, 43 cases (46.7%) showed p21waf1 expression, 23 cases (25.0%) showed cyclin D1 overexpression, and 61 cases (66.3%) showed Rb expression. No correlation was observed between the expressions of p21waf1, cyclin D1, and Rb. There was no association of p21waf1 and cyclin D1 immunoreactivity with gender, disease stage, or histological types of the tumor. Regarding the prognosis in 79 cases with complete resection, no statistical differences were observed according to the degree of expression of these three factors. However, when unfavorable prognostic factors were considered to be the positive expression of p21waf1, positive of cyclin D1, and negative of Rb, the 5-year disease-free survival rate in the group with 2 or 3 unfavorable prognostic factors was 21.1%, which was statistically poorer than the 45.4% in the group with 0 or 1 unfavorable prognostic factor (p=0.0138). We conclude that examination of the expression of cell cycle regulators, such as p21waf1, cyclin D1, and Rb, is useful as a prognostic indicator, when these proteins' expression is analyzed in combination.     

乳腺癌组织中nm23、c-erbB-2、p53表达与临床病理特征的关系

目的　研究乳腺癌组织中nm 2 3、c erbB 2、p5 3基因蛋白的表达与临床病理特征的关系。方法　采用免疫组化S -P法 ,分别检测 76例乳腺癌、10例乳腺良性病变组织中nm 2 3、c erbB 2、p5 3基因蛋白的表达。 结果　c erbB 2、p5 3蛋白在乳腺良恶性病变之间的表达率有显著性差异 (P <0 .0 5 ,P <0 .0 1)。nm 2 3、c erbB 2蛋白表达与乳腺癌的组织学分级有关 (P <0 .0 5 ,P <0 .0 1)。 3种基因蛋白的表达均与腋窝淋巴结转移相关 (P <0 .0 1) ,与乳腺癌的组织学类型、患者年龄及肿瘤大小无关 (P >0 .0 5 )。在乳腺癌组织中 ,nm 2 3与c erbB 2、nm 2 3与 p5 3的表达呈均负相关 (P <0 .0 1,P <0 .0 5 ) ,c erbB 2与p5 3的表达则呈正相关 (P <0 .0 5 )。结论　nm 2 3、c erbB 2、p5 3基因参与乳腺癌的发生发展过程。联合检测nm 2 3、c erbB 2、p5 3基因蛋白对预测乳腺癌淋巴结转移及判断预后有重要意义